In Clinical

Follow this topic

Bookmark

Record learning outcomes

AstraZeneca has announced the results from the EXSCEL (EXenatide Study of Cardiovascular Event Lowering) trial that showed cardiovascular safety with Bydureon (exenatide extended-release) in patients with type 2 diabetes at a wide range of CV risk.

The drug was found not to increase the incidence of major adverse cardiovascular events (MACE), a composite endpoint of CV death, non-fatal heart attack or non-fatal stroke, compared to placebo. There were also fewer CV events observed in the exenatide arm of the trial.